Literature DB >> 22387541

Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity.

Qingchang Li1, Qianze Dong, Enhua Wang.   

Abstract

Rsf-1 (HBXAP) was recently reported to be overexpressed in various cancers and associated with the malignant behavior of cancer cells. However, the expression of Rsf-1 in primary lung cancer and its biological roles in non-small cell lung cancer (NSCLC) have not been reported. The molecular mechanism of Rsf-1 in cancer aggressiveness remains ambiguous. In the present study, we analyzed the expression pattern of Rsf-1 in NSCLC tissues and found that Rsf-1 was overexpressed at both the mRNA and protein levels. There was a significant association between Rsf-1 overexpression and TNM stage (p=0.0220) and poor differentiation (p=0.0013). Furthermore, knockdown of Rsf-1 expression in H1299 and H460 cells with high endogenous Rsf-1 expression resulted in a decrease of colony formation ability and inhibition of cell cycle progression. Rsf-1 knockdown also induced apoptosis in these cell lines. Further analysis showed that Rsf-1 knockdown decreased cyclin D1 expression and phospho-ERK levels. In conclusion, Rsf-1 is overexpressed in NSCLC and contributes to malignant cell growth by cyclin D1 and ERK modulation, which makes Rsf-1 a candidate therapeutic target in lung cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387541     DOI: 10.1016/j.bbrc.2012.02.095

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.

Authors:  Yeong-In Yang; Ji-Hye Ahn; Kyung-Tae Lee; Ie-Ming Shih; Jung-Hye Choi
Journal:  Cancer Res       Date:  2014-02-24       Impact factor: 12.701

2.  Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma.

Authors:  Xiuwei Zhang; Dongwei Xue; Fengxia Hao; Lingling Xie; Jiani He; Junda Gai; Yuhui Liu; Hongtao Xu; Qingchang Li; Enhua Wang
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

3.  Integration of genomic data enables selective discovery of breast cancer drivers.

Authors:  Félix Sanchez-Garcia; Patricia Villagrasa; Junji Matsui; Dylan Kotliar; Verónica Castro; Uri-David Akavia; Bo-Juen Chen; Laura Saucedo-Cuevas; Ruth Rodriguez Barrueco; David Llobet-Navas; Jose M Silva; Dana Pe'er
Journal:  Cell       Date:  2014-11-26       Impact factor: 41.582

4.  Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma.

Authors:  Chengyao Xie; Lin Fu; Lingling Xie; Nan Liu; Qingchang Li
Journal:  Tumour Biol       Date:  2014-05-06

5.  Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker.

Authors:  Hui Li; Yi Zhang; Yue Zhang; Xue Bai; Yang Peng; Ping He
Journal:  Tumour Biol       Date:  2014-03-01

6.  Quantification of serum HBXAP DNA in lung cancer patients by quantitative fluorescent polymerase chain reaction.

Authors:  Yu-Lei Hou; Hui Chen; Ming-Jian Ge; Feng-Zeng Li; Cheng-Jun Xue; Yan-Feng Wu; Hai-Xia Luo
Journal:  Mol Biol Rep       Date:  2013-03-02       Impact factor: 2.316

7.  Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.

Authors:  Jim Jinn-Chyuan Sheu; Jung Hye Choi; Bin Guan; Fuu-Jen Tsai; Chun-Hung Hua; Ming-Tsung Lai; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol       Date:  2013-02-04       Impact factor: 7.996

8.  Effects of RSF-1 on proliferation and apoptosis of breast cancer cells.

Authors:  Yuhui Liu; Junda Gai; Lin Fu; Xiuwei Zhang; Enhua Wang; Qingchang Li
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

Review 9.  RSF1 in cancer: interactions and functions.

Authors:  Guiyang Cai; Qing Yang; Wei Sun
Journal:  Cancer Cell Int       Date:  2021-06-19       Impact factor: 5.722

10.  RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer.

Authors:  Xiangyu Wang; Jim Jinn-Chyuan Sheu; Ming-Tsung Lai; Cherry Yin-Yi Chang; Xiugui Sheng; Ling Wei; Yongsheng Gao; Xingwu Wang; Naifu Liu; Wenli Xie; Chih-Mei Chen; Wendy Y Ding; Li Sun
Journal:  Biomedicine (Taipei)       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.